MX389761B - Una composicion farmaceutica que comprende rosuvastatina y ezetimibe y un metodo de preparacion de la misma. - Google Patents
Una composicion farmaceutica que comprende rosuvastatina y ezetimibe y un metodo de preparacion de la misma.Info
- Publication number
- MX389761B MX389761B MX2019002516A MX2019002516A MX389761B MX 389761 B MX389761 B MX 389761B MX 2019002516 A MX2019002516 A MX 2019002516A MX 2019002516 A MX2019002516 A MX 2019002516A MX 389761 B MX389761 B MX 389761B
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- ezetimibe
- rosuvastatin
- fluorophenyl
- preparing same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ2016-539A CZ2016539A3 (cs) | 2016-09-05 | 2016-09-05 | Farmaceutická kompozice obsahující dvě rozdílné účinné látky a způsob její přípravy |
| PCT/CZ2017/050037 WO2018041282A1 (en) | 2016-09-05 | 2017-08-31 | A pharmaceutical composition comprising rosuvastatin and ezetimibe and a preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019002516A MX2019002516A (es) | 2019-06-17 |
| MX389761B true MX389761B (es) | 2025-03-20 |
Family
ID=59955311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002516A MX389761B (es) | 2016-09-05 | 2017-08-31 | Una composicion farmaceutica que comprende rosuvastatina y ezetimibe y un metodo de preparacion de la misma. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11786526B2 (enExample) |
| EP (1) | EP3506888A1 (enExample) |
| JP (1) | JP7094944B2 (enExample) |
| KR (1) | KR102517765B1 (enExample) |
| CN (1) | CN110418637A (enExample) |
| CZ (1) | CZ2016539A3 (enExample) |
| EA (1) | EA201990652A1 (enExample) |
| IL (1) | IL265172B (enExample) |
| MA (1) | MA46100A (enExample) |
| MX (1) | MX389761B (enExample) |
| TW (1) | TWI811195B (enExample) |
| WO (1) | WO2018041282A1 (enExample) |
| ZA (1) | ZA201901342B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7115825B2 (ja) * | 2017-06-28 | 2022-08-09 | 日医工株式会社 | エゼチミブ含有経口製剤及びその製造方法 |
| JP2019014700A (ja) * | 2017-07-11 | 2019-01-31 | 大原薬品工業株式会社 | エゼチミブ含有口腔内崩壊錠及びその製造方法 |
| WO2021019499A1 (en) | 2019-07-31 | 2021-02-04 | TECNIMEDE - Sociedade Técnico-medicinal, SA | Solid oral multiple-unit immediate release compositions, methods and uses thereof |
| WO2022023206A1 (en) * | 2020-07-27 | 2022-02-03 | Krka, D.D., Novo Mesto | Bilayer tablet comprising ezetimibe and atorvastatin |
| CN120000605A (zh) * | 2025-04-21 | 2025-05-16 | 山东齐都药业有限公司 | 瑞舒伐他汀依折麦布制剂及其制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60319983T2 (de) * | 2003-09-01 | 2009-07-23 | Jpm - The Jordanian Pharmaceutical Manufacturing Co. Ltd. | Universelle Zusammensetzung zur kontrollierten Wirkstoffabgabe enthaltend Chitosan |
| WO2009024889A2 (en) | 2007-08-21 | 2009-02-26 | Ranbaxy Laboratories Limited | Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe |
| EP2168573A1 (en) | 2008-09-30 | 2010-03-31 | LEK Pharmaceuticals D.D. | Formulations comprising ezetimibe |
| EP2448919A2 (en) | 2009-07-02 | 2012-05-09 | Mahmut Bilgic | Solubility and stability enchancing pharmaceutical formulation |
| HUE038048T2 (hu) * | 2009-07-28 | 2018-09-28 | Egyt Gyogyszervegyeszeti Gyar | Új granulálási eljárás és ezzel elõállított granulátum |
| TR201009397A2 (tr) * | 2010-11-11 | 2012-05-21 | Bi̇lgi̇ç Mahmut | Rosuvastatin içeren farmasötik bileşimler. |
| WO2013066279A1 (en) | 2011-10-13 | 2013-05-10 | Mahmut Bilgic | Solid dosage forms comprising ezetimibe |
| US9763885B2 (en) * | 2012-05-01 | 2017-09-19 | Althera Laboratories Ltd. | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases |
| MX2012014970A (es) * | 2012-12-18 | 2013-08-27 | Hetlabs Mexico S A De C V | Composiciones farmaceuticas que comprenden ezetimiba y rosuvastatina de calcio amorfo novedoso. |
| HU231036B1 (hu) * | 2013-09-30 | 2019-12-30 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Koleszterin bioszintézis gátló hatóanyagot és koleszterin abszorpciót gátló hatóanyagot tartalmazó kombinációs gyógyszerkészítmény |
| CN103585157B (zh) * | 2013-11-13 | 2016-02-03 | 武汉武药科技有限公司 | 一种含依折麦布和瑞舒伐他汀的双层片及其制备方法 |
| KR20150079373A (ko) * | 2013-12-30 | 2015-07-08 | 한미약품 주식회사 | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 |
| KR101977785B1 (ko) * | 2014-06-25 | 2019-05-14 | 한미약품 주식회사 | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 및 그 제조방법 |
| FR3030251B1 (fr) * | 2014-12-22 | 2018-11-02 | L'oreal | Composition comprenant un compose 4-(heterocycloalkyl)-benzene-1,3-diol et un solvant particulier |
| CN105310993A (zh) | 2015-11-17 | 2016-02-10 | 深圳信立泰药业股份有限公司 | 一种含有依折麦布的药物组合物及其制备方法 |
-
2016
- 2016-09-05 CZ CZ2016-539A patent/CZ2016539A3/cs unknown
-
2017
- 2017-08-31 CN CN201780067887.8A patent/CN110418637A/zh active Pending
- 2017-08-31 TW TW106129702A patent/TWI811195B/zh active
- 2017-08-31 IL IL265172A patent/IL265172B/en unknown
- 2017-08-31 US US16/330,268 patent/US11786526B2/en active Active
- 2017-08-31 EA EA201990652A patent/EA201990652A1/ru unknown
- 2017-08-31 EP EP17771980.4A patent/EP3506888A1/en active Pending
- 2017-08-31 JP JP2019512660A patent/JP7094944B2/ja active Active
- 2017-08-31 MX MX2019002516A patent/MX389761B/es unknown
- 2017-08-31 MA MA046100A patent/MA46100A/fr unknown
- 2017-08-31 KR KR1020197009428A patent/KR102517765B1/ko active Active
- 2017-08-31 WO PCT/CZ2017/050037 patent/WO2018041282A1/en not_active Ceased
-
2019
- 2019-03-04 ZA ZA2019/01342A patent/ZA201901342B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA46100A (fr) | 2019-07-10 |
| TW201818938A (zh) | 2018-06-01 |
| MX2019002516A (es) | 2019-06-17 |
| TWI811195B (zh) | 2023-08-11 |
| JP2019526591A (ja) | 2019-09-19 |
| ZA201901342B (en) | 2020-10-28 |
| US20200009136A1 (en) | 2020-01-09 |
| CZ2016539A3 (cs) | 2018-03-14 |
| IL265172A (en) | 2019-05-30 |
| WO2018041282A1 (en) | 2018-03-08 |
| IL265172B (en) | 2022-09-01 |
| JP7094944B2 (ja) | 2022-07-04 |
| EA201990652A1 (ru) | 2019-08-30 |
| US11786526B2 (en) | 2023-10-17 |
| EP3506888A1 (en) | 2019-07-10 |
| CN110418637A (zh) | 2019-11-05 |
| KR20190045286A (ko) | 2019-05-02 |
| KR102517765B1 (ko) | 2023-04-03 |
| BR112019004269A2 (pt) | 2019-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX389761B (es) | Una composicion farmaceutica que comprende rosuvastatina y ezetimibe y un metodo de preparacion de la misma. | |
| SA520411007B1 (ar) | مركبات مضادة للتكاثر وطرق لاستخدامها | |
| PH12020552187A1 (en) | Pcsk9 antagonist compounds | |
| CY1123661T1 (el) | Κρυσταλλικη μορφη ενος αναστολεα της mdm2 | |
| MX384752B (es) | ANTAGONISTAS SOLUBLES DE RECEPTOR DE C5a (C5aR). | |
| EA202091324A1 (ru) | Комбинация 4-пиримидинсульфамидного производного с ингибитором sglt-2 для лечения заболеваний, связанных с эндотелином | |
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| EA201400230A1 (ru) | Фунгицидные замещенные 1-{2-[2-галоген-4-(4-галогенфенокси)фенил]-2-этоксиэтил}-1н-[1,2,4]триазольные соединения | |
| PE20141167A1 (es) | Piridopirazinas sustituidas como inhibidores novedosos de ptk | |
| NZ594332A (en) | Compounds for the prevention and treatment of cardiovascular disease | |
| PE20191647A1 (es) | Acidos propionicos 3-sustituidos como inhibidores de la integrina alfa v | |
| PE20161236A1 (es) | Compuesto de triazina y su uso para fines medicos | |
| WO2019165043A3 (en) | Indane-amines as pd-l1 antagonists | |
| EA201990279A1 (ru) | Гербицидные композиции, содержащие фенилпиримидины | |
| MA46608B1 (fr) | Formulation liposomale utile pour le traitement du cancer | |
| MA38865A1 (fr) | Formulation comprenant un agent hypolipidémiant | |
| EA201692542A1 (ru) | Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы | |
| EA201990678A1 (ru) | Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2 | |
| MX2014007878A (es) | Formulaciones de (+) - 2 - [1 - (3 - etoxi - 4 - metoxi - fenil) - 2 - metansulfonil - etil] - 4 - acetil aminoisoindolin - 1, 3 - diona. | |
| MX2021013576A (es) | Compuesto utilizado como inhibidor de la quinasa y aplicación del mismo. | |
| HK1220386A1 (zh) | Ep4受体拮抗剂在软骨疾病的治疗中的用途 | |
| MX371178B (es) | Orvepitant para el tratamiento de la tos crónica. | |
| EA201890361A1 (ru) | Производные 5-(n-бензил-тетрагидроизохинолин-6-ил)пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека | |
| MX353041B (es) | Formas y formulaciones de un compuesto de pirimidinilciclopentano, composiciones y métodos de este. | |
| MY205605A (en) | Subcutaneous administration of a p2y12 receptor antagonist |